INTRODUCTION
Antiviral drugs have become crucial in the management of several viral infections, including human HSV, HIV, HBV, HCV, and cytomegalovirus (HCMV) infections. Prominent among these drugs are nucleoside analogues, which can act as potent antiviral agents owing to their ability to inhibit viral polymerases. [1] Many publications have discussed the synthesis and antiviral activity of 5-modified 2 -deoxyuridine analogues. Several substituents have been introduced at C-5, including alkoxymethyl groups, [2] azoles, [3] and alkyloximes. [3] Several analogues proved moderately to highly active against HSV. These results showed that modification at position 5 of 2 -deoxyuridine represents an interesting approach in the search for new antiherpes agents. However, relatively few examples of 5-(hetero)aryl-modified nucleosides with promising antiviral activity have been reported. [4] This may be due to the fact that these nucleosides are not efficiently converted into their triphosphate form. The first step in this process, the phosphorylation of the nucleoside analogue into its 5 -monophosphate counterpart by nucleoside kinases, is often rate-limiting in the conversion to the active metabolite. One way to overcome this bottleneck is to devise prodrugs that are capable of delivering the nucleoside monophosphate intracellularly. [5, 6] Another approach to bypass the first phosphorylation step is to use phosphonate analogues that, after intracellular conversion into their corresponding diphosphophosphonate forms, can exhibit antiviral activities. This led us to investigate a small series of 2 -deoxyuridine analogues that combine different aromatic substituents at position 5 of the base with a 5 -methylene phosphonate group (Figure 1 ).
RESULTS AND DISCUSSION
The synthesis of a series of 5-(hetero)aryl-modified nucleoside phosphonates started from 3 -O-tert-butyldimethylsilyl-2 -deoxy-β-D-uridine [7] and is depicted in Scheme 1. Conversion of nucleoside 6 to the vinylic phosphonate 7 was accomplished following the two-step procedure described by Cosyn et al. [8] Catalytic hydrogenation of 7 in the presence of Pd/C afforded phosphonate 8, which was selectively brominated at C-5 of the pyrimidine moiety using N -bromosuccinimide in DMF. [9] Palladium-catalyzed crosscoupling with four commercial aryl and heteroaryl boronic acids gave access to 10-13. [10] After removing the silyl protecting group, deprotection of the phosphonate esters was performed using TMSBr in CH 2 Cl 2 . Concomitant anomerization during this last step resulted for each analogue in a 2:1 mixture of the α-and β-isomer that could be separated using RP-HPLC. Stereochemical assignment of compound 1a was based on the results of a ROESY experiment (Figure 2) . A clear rOe contact between H-4 and H-2 b (proton down) and a much weaker interaction between H-6 and H-2 b proved that H-4 and H-6 were not positioned at the same side of the furanose ring. The β-configuration of the nucleobase was further established by the presence of a strong interaction between H-6 and H-5 a,b. In an effort to synthesize the nonmodified 2 -deoxyuridine-5 -phosphonate analogue, compound 8 was successively treated with a 1M TBAF solution in THF and TMSBr in CH 2 Cl 2 (Scheme 2). In this case, attempts to separate the anomeric mixture using flash chromatography and RP-HPLC were unsuccessful. To avoid the anomerization issue, we attempted to deprotect 18 in the presence of TMSBr under different reaction conditions. Following the reaction via 31 P NMR, it was observed that anomerization started immediately after addition of TMSBr. We learned by attempts at different temperatures that no reaction occurred under −20
• C and that anomerization started simultaneously with the phosphonate hydrolysis, even at low temperature. Also, the addition of an acid scavenger (e.g., (trimethylsilyl)acetamide or 2,6-lutidine) could not prevent anomerization. [11] None of the tested compounds showed toxicity to any of the tested cell lines. However, the final compounds 1a-4a and 1b-4b failed to show antiviral activity against HSV-1, HSV-2, VV, VSV, HSV-1 TK, − and different VZV strains. Also, in the human T-lymphocyte (CEM) cell cultures, none of these compounds showed activity against HIV-1 or HIV-2. Very weak antiviral activity was observed for the β-analogue 3a and the α-analogue 2b against HCMV Davies and HCMV AD-169, respectively, whereas compounds 2a and 4a showed weak activity against both HCMV strains ( Table 1 ). The most active compound of this series, analogue 2a, was at least 6 or 50 times less active than ganciclovir and cidofovir, respectively. The lack of biological activity of these derivatives might be attributed to several features, including 1) their inability to diffuse through the cell membrane; 2) their ineffective conversion to the corresponding diphosphophosphonate analogue; or 3) their weak affinity for the target polymerases and/or lack of incorporation into viral RNA. If uptake into the cell would be the bottleneck, converting the phosphonates to an appropriate prodrug form could be considered.
CONCLUSION
In conclusion, this study described the synthesis, structural analysis, and antiviral activity of a small series of 2 -deoxyuridine analogues that combine different aromatic substituents at position 5 of the base and a 5 -methylene phosphonate modification at the sugar moiety. All compounds were synthesized via an 8-step procedure, featuring a Wittig reaction and Suzuki-Miyaura coupling. An unexpected anomerization during the last step of the synthesis allowed us to investigate the β-as well as the α-anomers of the corresponding phosphonates. None of these analogues exhibited significant antiviral activity.
EXPERIMENTAL General Synthesis
All reagents were from standard commercial sources and of analytical grade. Precoated Merck silica gel F254 plates were purchased for TLC; spots were examined under ultraviolet light at 254 nm and further visualized by sulfuric acid-anisaldehyde spray. Column chromatography was performed on silica gel (63-200 µm, 60 Å , Biosolve, Valkenswaard, Netherlands). With the exception of the 13 C NMR spectrum of compound 1a, which was recorded on a 500 MHz Bruker DRX apparatus, all NMR spectra were determined using a Varian Mercury 300 MHz spectrometer. Chemical shifts are given in ppm (δ) relative to the residual solvent signals, which in the case of DMSOd 6 were 2.54 ppm for 1 H and 40.5 ppm for 13 C. Structural assignment was confirmed with COSY and DEPT. All signals assigned to hydroxyl groups were exchangeable with D 2 O. Exact mass measurements were performed on a Waters LCT Premier XETM time of flight (TOF) mass spectrometer equipped with a standard electrospray ionization (ESI) and modular LockSpray TM interface (Waters Corp., Milford, MA, USA). Samples were infused in a CH 3 CN/water (1:1) mixture at 10 µL/min.
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-hex-5-enofuranosyl]-uracil (7)
2 -Iodoxybenzoic acid (550 mg, 1.97 mmol) was added to a solution of 6 (449 mg, 1.31 mmol) in CH 3 CN (12 mL) and the resulting suspension was stirred at 80
• C for 6 hours. After cooling in an ice bath (15 minutes), the solid was removed by filtration and washed with cold CH 3 CN. The solvent was evaporated and the residue was co-distilled with toluene. The residue was dissolved in anhydrous DMSO (3.4 mL) and freshly prepared [(diethoxyphosphinyl)methyl]triphenylphosphorane in DMSO (3.4 mL) was added. After 20 hours, the mixture was poured into water and extracted with CH 2 Cl 2 . The combined organic layers were dried over MgSO 4 , filtered, and concentrated in vacuo. The residue was lyophilized to remove the remaining DMSO and purified on a silica gel column (CH 2 Cl 2 /MeOH 98:2) yielding 257 mg (41%) of 7 as a colourless solid. 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-Dhexofuranosyl]-uracil (8)
To a solution of compound 7 (257 mg, 0.54 mmol) in MeOH (8 mL) was added 10% Pd/C. The reaction mixture was stirred under hydrogen atmosphere overnight. The catalyst was removed by filtration through Celite and the filtrate was evaporated to yield pure compound 8 (250 mg, 97%) as a colorless solid. 1 
General Procedure for the Synthesis of 5-Modified Nucleoside Phosphonates via Suzuki-Miyaura Coupling
A mixture of compound 9 (1 equiv.), aryl boronic acid (2 equiv.), Pd(PPh 3 ) 4 (0.1 equiv.) and Na 2 CO 3 (3.3 equiv.) in DMF and degassed H 2 O was heated (± 130
• C, oil bath) under argon for 6 hours or until TLC indicated consumption of all starting material. The mixture was then concentrated and co-distilled with toluene. The residue was purified by column chromatography (CH 2 Cl 2 /MeOH 94:6-98:2), affording the 5-modified analogues in moderate yield.
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-Dhexofuranosyl]-5-phenyluracil (10)
Reaction of compound 9 (153 mg, 0.27 mmol) with phenylboronic acid (68 mg, 0.55 mmol), Pd(PPh 3 ) 4 (32 mg, 0.027 mmol) and Na 2 CO 3 (96 mg, 0.91 mmol) in DMF (6.5 mL) and degassed H 2 O (0.8 mL) was performed as described in the general procedure to yield compound 10 as a colorless solid (120 mg, 79%). 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-Dhexofuranosyl]-5-(4-fluorophenyl)uracil (12)
Reaction of compound 9 (163 mg, 0.29 mmol) with 4-fluorophenylboronic acid (82 mg, 0.59 mmol), Pd(PPh 3 ) 4 (34 mg, 0.029 mmol) and Na 2 CO 3 (102 mg, 0.97 mmol) in DMF (7 mL) and degassed H 2 O (0.9 mL) was performed as described in the general procedure to yield compound 12 as a colorless solid (141 mg, 84%). 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-Dhexofuranosyl]-5-(thiophen-2-yl)uracil (13)
Reaction of compound 9 (155 mg, 0.28 mmol) with thiophene-2-boronic acid (71 mg, 0.56 mmol), Pd(PPh 3 ) 4 (32 mg, 0.028 mmol) and Na 2 CO 3 (98 mg, 0.92 mmol) in DMF (6.7 mL) and degassed H 2 O (0.8 mL) was performed as described in the general procedure to yield compound 13 as a colorless solid (117 mg, 75%). 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-5-phenyluracil (14)
Compound 10 (115 mg, 0.21 mmol) was dissolved in THF (1.3 mL). A solution of 1 M TBAF in THF (0.46 mmol, 0.46 mL) was added. After stirring for 1 hour at room temperature, the reaction was completed. The solvent was evaporated and the dry residue was purified by column chromatography (CH 2 Cl 2 /MeOH 96:4) to give pure compound 14 (65 mg, colorless solid) in 71% yield. 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-5-(4-fluorophenyl)-uracil (16)
Compound 12 (135 mg, 0.24 mmol) was deprotected using the same procedure as described for the synthesis of compound 14. Compound 16 was obtained as a colorless solid in a 32% yield (35 mg). 1 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-5-(thiophen-2-yl)-uracil (17)
Compound 13 (117 mg, 0.21 mmol) was deprotected using the same procedure as described for the synthesis of compound 14. Compound 17 was obtained as a colorless solid in a 63% yield (59 mg). 1 H NMR (300 MHz, CDCl 3 ): δ 1.31 (6H, app dt, J = 2.1 Hz, J = 6.9 Hz, 2 x OCH 2 CH 3 ), 1.86-2.08 (4H, m, H-5 a, H-5 b, H-6 a and H-6 b), 2.18-2.27 (1H, m, H-2 a), 2.46-2.54  (1H, m, H-2 b), 3.97-3.98 (1H, m, H-4 
General Procedure for the Deprotection of 5-Modified Nucleoside Phosphonates
The phosphonic ester (1 equiv.) was dissolved in CH 2 Cl 2 under argon. TMSBr (2 equiv.) was added and the resulting solution was stirred overnight. The solvent was evaporated and the residue dissolved in a mixture of EtOAc/Et 2 O (1:1) and water. The organic phase was washed with water and the water layers were combined and lyophilized. Purification of the crude using RP-HPLC (Phenomenex Luna C-18, H 2 O/0.1% HCOOH in CH 3 CN, 90:10 → 0:100 in 23 minutes, flow 17.5 mL/minute) afforded 2 series of compounds: the α-(retention time ≥ 12 minutes) and β-isomer (retention time ≈ 10-11 minutes) of each phosphonate.
1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-hexofuranosyl]-5-phenyl uracil (1a) and 1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-α-D-hexofuranosyl]-5-phenyluracil (1b)
Reaction of compound 14 (27 mg, 0.061 mmol) with TMSBr (16 µL, 0.12 mmol) in CH 2 Cl 2 (0.9 mL) as described in the general procedure affording the β-(1a, 0.9 mg, 4%) and α-isomer (1b, 3.2 mg, 14%) as white powders. 
Experimental Assay

Antiviral and Cytotoxicity Assays for Compounds 1a-4b
The antiviral activity of the new compounds was determined using a cytopathogenicity assay against herpes simplex virus type 1 (HSV-1) (KOS 
